Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) EBIT (2016 - 2025)

Historic EBIT for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$116.9 million.

  • Agios Pharmaceuticals' EBIT fell 1367.36% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$475.6 million, marking a year-over-year decrease of 1685.94%. This contributed to the annual value of -$425.7 million for FY2024, which is 874.87% down from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EBIT stood at -$116.9 million, which was down 1367.36% from -$127.1 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' EBIT registered a high of -$90.6 million during Q1 2023, and its lowest value of -$127.1 million during Q2 2025.
  • In the last 5 years, Agios Pharmaceuticals' EBIT had a median value of -$100.9 million in 2023 and averaged -$101.9 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 11118.96% in 2021, then soared by 1041.28% in 2023.
  • Over the past 5 years, Agios Pharmaceuticals' EBIT (Quarter) stood at -$104.8 million in 2021, then rose by 5.39% to -$99.2 million in 2022, then decreased by 7.16% to -$106.3 million in 2023, then dropped by 17.65% to -$125.0 million in 2024, then rose by 6.53% to -$116.9 million in 2025.
  • Its EBIT was -$116.9 million in Q3 2025, compared to -$127.1 million in Q2 2025 and -$106.6 million in Q1 2025.